Geoffrey Porges
Stock Analyst at SVB Leerink
(1.46)
# 3,592
Out of 5,138 analysts
113
Total ratings
46.67%
Success rate
-1.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $25.52 | +119.44% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $21.95 | +355.58% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $733.78 | +15.84% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $70.43 | -31.85% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $331.00 | -34.74% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $214.04 | -36.93% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $22.98 | -52.13% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $124.14 | -39.58% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $45.74 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $20.42 | -51.03% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $442.08 | -60.41% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $26.80 | +213.43% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $47.65 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $13.82 | +341.39% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $165.38 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $25.52
Upside: +119.44%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $21.95
Upside: +355.58%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $733.78
Upside: +15.84%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $70.43
Upside: -31.85%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $331.00
Upside: -34.74%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $214.04
Upside: -36.93%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $22.98
Upside: -52.13%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $124.14
Upside: -39.58%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $45.74
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $20.42
Upside: -51.03%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $442.08
Upside: -60.41%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $26.80
Upside: +213.43%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $47.65
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $13.82
Upside: +341.39%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $165.38
Upside: -